CoChat

Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells

Open access
Lee, Chaeyoung, Yi, Jawoon, Park, Jihwan, Ahn, Byungyong, Won, Young-Wook, Jeon, JiHeung, Lee, Byung Ju, Cho, Wha Ja, Park, Jeong Woo · 2024 · Cell Death & Disease

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Although KRAS G12C inhibitors have shown promising activity in lung adenocarcinomas harbouring KRAS G12C, acquired resistance to these therapies eventually occurs in most patients. Re-expression of KRAS is thought to be one of the main causes of acquired resistance. However, the mechanism through which cancer cells re-express KRAS is not fully understood. Here, we report that the Hedgehog signal is induced by KRAS G12C inhibitors and mediates KRAS re-expression in cancer cells treated with a KRAS G12C inhibitor. Further, KRAS G12C inhibitors induced the formation of primary cilia and activated the Hedgehog-GLI-1 pathway. GLI-1 binds to the KRAS promoter region, enhancing KRAS promoter activity and KRAS expression. Inhibition of GLI using siRNA or the smoothened (Smo) inhibitor suppressed re-expression of KRAS in cells treated with a KRAS G12C inhibitor. In addition, we demonstrate that KRAS G12C inhibitors decreased Aurora kinase A (AURKA) levels in cancer cells, and inhibition of AURKA using siRNA or inhibitors led to increased expression levels of GLI-1 and KRAS even in the absence of KRAS inhibitor. Ectopic expression of AURKA attenuated the effect of KRAS G12C inhibitors on the expression of GLI-1 and re-expression of KRAS. Together, these findings demonstrate the important role of AURKA, primary cilia, and Hedgehog signals in the re-expression of KRAS and therefore the induction of acquired resistance to KRAS G12C inhibitors, and provide a rationale for targeting Hedgehog signalling to overcome acquired resistance to KRAS G12C inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-024-06436-9

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The KRASG12C inhibitor ARS-1620 induces re-expression of KRAS and reactivation of ERK signal in lung cancer cells. A, B and F H23 and C, D and G H358 lung cancer cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in ERK phosphorylation and accumulation of KRAS-GTP in H23 (A, B) and H358 cells (C, D) were determined by western blot analysis. Time-dependent changes in KRAS mRNA levels in H23 (F) and H358 cells (G) were determined by qRT-PCR. Fold-change in expression level was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation (n = 3 independent experiments) (one-way ANOVA, **P < 0.01; ***P < 0.001). E Representative plots of flow cytometry using propidium iodide staining for cell cycle analysis of H358 cells. Graphs represent the mean ± standard deviation (n = 3 independent experiments).
Fig. 1 The KRASG12C inhibitor ARS-1620 induces re-expression of KRAS and reactivation of ERK signal in lung cancer cells. A, B and F H23 and C, D and G H358 lung cancer cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in ERK phosphorylation and accumulation of KRAS-GTP in H23 (A, B) and H358 cells (C, D) were determined by western blot analysis. Time-dependent changes in KRAS mRNA levels in H23 (F) and H358 cells (G) were determined by qRT-PCR. Fold-change in expression level was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation (n = 3 independent experiments) (one-way ANOVA, **P < 0.01; ***P < 0.001). E Representative plots of flow cytometry using propidium iodide staining for cell cycle analysis of H358 cells. Graphs represent the mean ± standard deviation (n = 3 independent experiments).CC BY · PubMed Central
Fig. 2 RNA-seq analysis reveals induced Hedgehog signals in lung cancer cells at 48 h after ARS-1620 treatment. H358 cells were treated with combination of 10 μM ARS-1620 and 10 μM sonidegib for 12 h or 48 h and their transcriptome profiles were analyzed by RNA-seq. A Heat map of 947 genes upregulated at 48 h after treatment with ARS-1620 in H358 cells versus non-treated cells (n = 3 independent experiments). B Heat map of 14 Hedgehog signaling–related genes. C, D Gene set enrichment plots of Hedgehog signaling was negatively enriched in cells at 12 h after ARS-1620 treatment (C) and positively enriched in cells at 48 h after ARS-1620 treatment versus non-treated cells (D). E Volcano plots of differentially expressed genes (DEGs) in cells treated with ARS-1620 for 48 h compared with cells treated with ARS-1620 for 12 h. The y-axis corresponds to the significance level represented by the −log10 P value, and the x-axis displays the log2 (FC) value. Red dots represent significant (adj. P < 0.05 and |log2FC | ≥ 1.5) DEGs. Dotted horizontal line indicates P = 0.05, and the dotted vertical line indicates a mean |log2FC| of 1.5. F–J Gene set enrichment plots of F KRAS signaling and G Hedgehog signaling positively were enriched in cells treated with ARS-1620 for 48 h versus cells treated with ARS-1620 for 12 h. H Bar plot of enriched GSEA pathways in cells treated with ARS-1620 for 48 h versus cells treated with ARS-1620 for 12 h. I Enrichment plot of KRAS signaling negatively enriched in cells treated with ARS-1620 and sonidegib for 48 h versus cells treated with ARS-1620 for 48 h. J Bar plot of enriched GSEA pathways in cells treated with ARS-1620 and sonidegib for 48 h versus cells treated with ARS-1620 for 48 h.
Fig. 2 RNA-seq analysis reveals induced Hedgehog signals in lung cancer cells at 48 h after ARS-1620 treatment. H358 cells were treated with combination of 10 μM ARS-1620 and 10 μM sonidegib for 12 h or 48 h and their transcriptome profiles were analyzed by RNA-seq. A Heat map of 947 genes upregulated at 48 h after treatment with ARS-1620 in H358 cells versus non-treated cells (n = 3 independent experiments). B Heat map of 14 Hedgehog signaling–related genes. C, D Gene set enrichment plots of Hedgehog signaling was negatively enriched in cells at 12 h after ARS-1620 treatment (C) and positively enriched in cells at 48 h after ARS-1620 treatment versus non-treated cells (D). E Volcano plots of differentially expressed genes (DEGs) in cells treated with ARS-1620 for 48 h compared with cells treated with ARS-1620 for 12 h. The y-axis corresponds to the significance level represented by the −log10 P value, and the x-axis displays the log2 (FC) value. Red dots represent significant (adj. P < 0.05 and |log2FC | ≥ 1.5) DEGs. Dotted horizontal line indicates P = 0.05, and the dotted vertical line indicates a mean |log2FC| of 1.5. F–J Gene set enrichment plots of F KRAS signaling and G Hedgehog signaling positively were enriched in cells treated with ARS-1620 for 48 h versus cells treated with ARS-1620 for 12 h. H Bar plot of enriched GSEA pathways in cells treated with ARS-1620 for 48 h versus cells treated with ARS-1620 for 12 h. I Enrichment plot of KRAS signaling negatively enriched in cells treated with ARS-1620 and sonidegib for 48 h versus cells treated with ARS-1620 for 48 h. J Bar plot of enriched GSEA pathways in cells treated with ARS-1620 and sonidegib for 48 h versus cells treated with ARS-1620 for 48 h.CC BY · PubMed Central
Fig. 3 The KRASG12C inhibitor ARS-1620 induces primary cilia formation and Hedgehog signaling in lung cancer cells. A–J The KRASG12C inhibitor ARS-1620 enhances Hedgehog signaling in lung cancer cells. A–E H23 and F–J H358 cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in GLI-1 (A, F), PTCH1 (B, G), IFT88 (C, H), and ARL6 (D, I) mRNA levels were determined by qRT-PCR amplification. Fold change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in ERK phosphorylation in H23 (E) and H358 cells (J) were determined by western blot analysis. K–P The KRASG12C inhibitor ARS-1620 induces primary cilia formation in lung cancer cells. K–M H23 and N–P H358 cells were treated with 10 μM ARS-1620 for 72 h and then stained for acetylated tubulin (Ac-Tu, red), Arl13B (green), and DAPI (blue). K, N Representative confocal microscopy images of H23 (K) and H358 (N) cells. L, O, M, P Percentages of ciliated H23 (L) and H358 cells (O) and the average length of cilia of H23 (M) and H358 cells (P) presented as the mean ± standard deviation (n = 150 pooled from three independent experiments). Student’s t-test, *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 3 The KRASG12C inhibitor ARS-1620 induces primary cilia formation and Hedgehog signaling in lung cancer cells. A–J The KRASG12C inhibitor ARS-1620 enhances Hedgehog signaling in lung cancer cells. A–E H23 and F–J H358 cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in GLI-1 (A, F), PTCH1 (B, G), IFT88 (C, H), and ARL6 (D, I) mRNA levels were determined by qRT-PCR amplification. Fold change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in ERK phosphorylation in H23 (E) and H358 cells (J) were determined by western blot analysis. K–P The KRASG12C inhibitor ARS-1620 induces primary cilia formation in lung cancer cells. K–M H23 and N–P H358 cells were treated with 10 μM ARS-1620 for 72 h and then stained for acetylated tubulin (Ac-Tu, red), Arl13B (green), and DAPI (blue). K, N Representative confocal microscopy images of H23 (K) and H358 (N) cells. L, O, M, P Percentages of ciliated H23 (L) and H358 cells (O) and the average length of cilia of H23 (M) and H358 cells (P) presented as the mean ± standard deviation (n = 150 pooled from three independent experiments). Student’s t-test, *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Fig. 4 Downregulation of AURKA by ARS-1620 mediates the induction of Hedgehog signaling and re-expression of KRAS. A–D ARS-1620 treatment downregulates the expression of AURKA in lung cancer cells. H23 (A, B) and H358 (C, D) cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in mRNA (A, C) and protein levels of AURKA (B, D) were determined by qRT-PCR and western blot analysis, respectively. Fold change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). E–K Inhibition of AURKA using siRNA (E–H) or an inhibitor (Tozasertib) (I–K) induced Hedgehog signaling and accumulation of KRAS-GTP. H358 cells were transfected with control scRNA or siRNA against AURKA (siAURKA) or treated with a 10 μM inhibitor. Expression levels of AURKA (E, H, and K), GLI-1 (F, H, I, and K), and KRAS (G, H, J, and K) were determined by qRT-PCR amplification and Western blot analysis. L–N Ectopic expression of AURKA attenuates the induction of Hedgehog signals and re-expression of KRAS in ARS-1620-treated cells. H358 cells were transfected with p-Aurora A GFP-AURKA-GFP expression vector or empty vector as a control, followed by treatment with 10 μM ARS-1620 for the indicated times. L Expression of AURKA was confirmed by qRT-PCR amplification, as were time-dependent changes in M GLI-1, and N KRAS mRNAs. Fold-change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). O Ectopic expression of AURKA blocks ARS-1620–mediated activation of KRAS promoter. H358 cells were co-transfected with the luciferase reporter vector pEZX-PG04.1/KRAS promoter and p-Aurora A GFP-AURKA-GFP expression vector or empty vector served as a control, followed by treatment with 10 μM ARS-1620 for 48 h. The same volume of dimethylsulfoxide was added to the cells as controls. The fold change in luciferase activity was calculated relative to that of empty vector-transfected dimethylsulfoxide control. The graphs are the mean ± standard deviation of three independent experiments (one-way ANOVA, ***P < 0.001).
Fig. 4 Downregulation of AURKA by ARS-1620 mediates the induction of Hedgehog signaling and re-expression of KRAS. A–D ARS-1620 treatment downregulates the expression of AURKA in lung cancer cells. H23 (A, B) and H358 (C, D) cells were treated with 10 μM ARS-1620 for the indicated times. Time-dependent changes in mRNA (A, C) and protein levels of AURKA (B, D) were determined by qRT-PCR and western blot analysis, respectively. Fold change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). E–K Inhibition of AURKA using siRNA (E–H) or an inhibitor (Tozasertib) (I–K) induced Hedgehog signaling and accumulation of KRAS-GTP. H358 cells were transfected with control scRNA or siRNA against AURKA (siAURKA) or treated with a 10 μM inhibitor. Expression levels of AURKA (E, H, and K), GLI-1 (F, H, I, and K), and KRAS (G, H, J, and K) were determined by qRT-PCR amplification and Western blot analysis. L–N Ectopic expression of AURKA attenuates the induction of Hedgehog signals and re-expression of KRAS in ARS-1620-treated cells. H358 cells were transfected with p-Aurora A GFP-AURKA-GFP expression vector or empty vector as a control, followed by treatment with 10 μM ARS-1620 for the indicated times. L Expression of AURKA was confirmed by qRT-PCR amplification, as were time-dependent changes in M GLI-1, and N KRAS mRNAs. Fold-change in expression levels was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). O Ectopic expression of AURKA blocks ARS-1620–mediated activation of KRAS promoter. H358 cells were co-transfected with the luciferase reporter vector pEZX-PG04.1/KRAS promoter and p-Aurora A GFP-AURKA-GFP expression vector or empty vector served as a control, followed by treatment with 10 μM ARS-1620 for 48 h. The same volume of dimethylsulfoxide was added to the cells as controls. The fold change in luciferase activity was calculated relative to that of empty vector-transfected dimethylsulfoxide control. The graphs are the mean ± standard deviation of three independent experiments (one-way ANOVA, ***P < 0.001).CC BY · PubMed Central
Fig. 5 Inhibition of hedgehog signal suppresses re-expression of KRAS and reactivation of ERK in KRASG12C inhibitor–treated lung cancer cells. H358 cells were co-treated with 10 μM ARS-1620 and 10 μM Smo inhibitor sonidegib for the indicated times. A Transcriptome profiles were analyzed by RNA-seq as described in Fig. 1 legends. Gene set enrichment plot of KRAS signaling negatively enriched in cells co-treated with ARS-1620 and the Hedgehog signal inhibitor sonidegib for 48 h versus cells treated with ARS-1620 for 48 h. B–I The Smo inhibitor sonidegib suppressed ARS-1620-induced Hedgehog signaling in both H23 (B–E) and H358 cells (F–I). Time-dependent changes in IFT88 (B, F), ARL6 (C, G), and GLI-1 mRNA levels (D, H) were determined by qRT-PCR amplification. Fold change in expression level was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in IFT88, ARL6 and GLI-1 shown in H23 (E) and H358 cells (I) were determined by western blot analysis. J–O The Smo inhibitor sonidegib suppresses ARS-1620-induced primary cilia formation in both H23 (J–L) and H358 cells (M–O). Representative confocal microscopy images of H23 (J) and H358 cells (M) stained for acetylated tubulin (Ac-Tu, red), Arl13B (green), and DAPI (blue). K, L, N, O Graphs depict the percentages of ciliated H23 (K) and H358 cells (N) and average length of cilia of H23 (L) and H358 cells (O) and are presented as the mean ± standard deviation (n = 150 pooled from three independent experiments). Student’s t-tests, *P < 0.05; **P < 0.01; ***P < 0.001. P–S The Smo inhibitor sonidegib suppresses ARS-1620–induced re-expression and reactivation of ERK signal in lung cancer cells. Time-dependent changes in KRAS mRNA levels in H23 (P) and H358 cells (R) were determined by qRT-PCR amplification. Fold change in expression level was relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in ERK phosphorylation in H23 (Q) and H358 cells (S) were determined by western blot analysis (T, U). The Smo inhibitor sonidegib suppressed the generation of cells resistant to KRASG12C inhibitors. At the indicated times, H23 (T) and H358 cells (U) were stained with crystal violet and photographed. Three independent experiments were performed and representative images are shown.
Fig. 5 Inhibition of hedgehog signal suppresses re-expression of KRAS and reactivation of ERK in KRASG12C inhibitor–treated lung cancer cells. H358 cells were co-treated with 10 μM ARS-1620 and 10 μM Smo inhibitor sonidegib for the indicated times. A Transcriptome profiles were analyzed by RNA-seq as described in Fig. 1 legends. Gene set enrichment plot of KRAS signaling negatively enriched in cells co-treated with ARS-1620 and the Hedgehog signal inhibitor sonidegib for 48 h versus cells treated with ARS-1620 for 48 h. B–I The Smo inhibitor sonidegib suppressed ARS-1620-induced Hedgehog signaling in both H23 (B–E) and H358 cells (F–I). Time-dependent changes in IFT88 (B, F), ARL6 (C, G), and GLI-1 mRNA levels (D, H) were determined by qRT-PCR amplification. Fold change in expression level was calculated relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in IFT88, ARL6 and GLI-1 shown in H23 (E) and H358 cells (I) were determined by western blot analysis. J–O The Smo inhibitor sonidegib suppresses ARS-1620-induced primary cilia formation in both H23 (J–L) and H358 cells (M–O). Representative confocal microscopy images of H23 (J) and H358 cells (M) stained for acetylated tubulin (Ac-Tu, red), Arl13B (green), and DAPI (blue). K, L, N, O Graphs depict the percentages of ciliated H23 (K) and H358 cells (N) and average length of cilia of H23 (L) and H358 cells (O) and are presented as the mean ± standard deviation (n = 150 pooled from three independent experiments). Student’s t-tests, *P < 0.05; **P < 0.01; ***P < 0.001. P–S The Smo inhibitor sonidegib suppresses ARS-1620–induced re-expression and reactivation of ERK signal in lung cancer cells. Time-dependent changes in KRAS mRNA levels in H23 (P) and H358 cells (R) were determined by qRT-PCR amplification. Fold change in expression level was relative to the values at time 0 for each cell. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, **P < 0.01; ***P < 0.001). Time-dependent changes in ERK phosphorylation in H23 (Q) and H358 cells (S) were determined by western blot analysis (T, U). The Smo inhibitor sonidegib suppressed the generation of cells resistant to KRASG12C inhibitors. At the indicated times, H23 (T) and H358 cells (U) were stained with crystal violet and photographed. Three independent experiments were performed and representative images are shown.CC BY · PubMed Central
Fig. 6 GLI-1 is required to induce KRAS expression in KRASG12C inhibitor–treated cells. A Ectopic expression of GLI-1 activates KRAS promoters. H358 cells were co-transfected with the luciferase reporter vector pEZX-PG04.1/KRAS promoter and pCMV6-Entry GLI-1 expression vector, with an empty vector used as a control. The fold change in luciferase activity was calculated relative to that of cells transfected with the pEZX-PG04.1/KRAS reporter vector only. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, ***P < 0.001). B GLI-1 binds to the KRAS promoter region. H358 cells were co-treated with 10 μM ARS-1620 and 10 μM sonidegib for 24 h. Chromatin immunoprecipitation–qPCR amplification was conducted to quantitate binding of GLI-1 to KRAS promoter. Fold-enrichment of the KRAS promoter was calculated relative to isotype control. The values represent mean ± standard deviation (n = 3) (one-way ANOVA, ***P < 0.001). C–F Inhibition of GLI-1 attenuates ARS-1620–induced accumulation of KRAS-GTP. H358 cells were transfected with siRNA #1 against GLI-1, followed by 10 μM ARS-1620 treatment for 48 h. Scrambled scRNA was used as a control. Changes in the GLI-1 (C, F), PTCH-1 (D), and KRAS levels (E, F) were determined by qRT-PCR and Western blot analysis. Fold change in expression levels was calculated relative to the values of scRNA-treated cells at time 0. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, *P < 0.01; ***P < 0.001).
Fig. 6 GLI-1 is required to induce KRAS expression in KRASG12C inhibitor–treated cells. A Ectopic expression of GLI-1 activates KRAS promoters. H358 cells were co-transfected with the luciferase reporter vector pEZX-PG04.1/KRAS promoter and pCMV6-Entry GLI-1 expression vector, with an empty vector used as a control. The fold change in luciferase activity was calculated relative to that of cells transfected with the pEZX-PG04.1/KRAS reporter vector only. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, ***P < 0.001). B GLI-1 binds to the KRAS promoter region. H358 cells were co-treated with 10 μM ARS-1620 and 10 μM sonidegib for 24 h. Chromatin immunoprecipitation–qPCR amplification was conducted to quantitate binding of GLI-1 to KRAS promoter. Fold-enrichment of the KRAS promoter was calculated relative to isotype control. The values represent mean ± standard deviation (n = 3) (one-way ANOVA, ***P < 0.001). C–F Inhibition of GLI-1 attenuates ARS-1620–induced accumulation of KRAS-GTP. H358 cells were transfected with siRNA #1 against GLI-1, followed by 10 μM ARS-1620 treatment for 48 h. Scrambled scRNA was used as a control. Changes in the GLI-1 (C, F), PTCH-1 (D), and KRAS levels (E, F) were determined by qRT-PCR and Western blot analysis. Fold change in expression levels was calculated relative to the values of scRNA-treated cells at time 0. The graphs are mean ± standard deviation of three independent experiments (one-way ANOVA, *P < 0.01; ***P < 0.001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 12

Metadata

Authors
Lee, C., Yi, J., Park, J., Ahn, B., Won, Y.-W., Jeon, J., Lee, B. J., Cho, W. J., & Park, J. W.
Affiliations
  • University of Ulsan (KR)
  • Gwangju Institute of Science and Technology (KR)
  • University of North Texas (US)
Corresponding author
  • Park, Jihwan
  • Cho, Wha Ja
  • Park, Jeong Woo
Venue
Cell Death & Disease
Published
2024-01-16
Volume
15
Issue
1
Pages
56-56
ISSN
2041-4889 (ISSN-L)
OpenAlex
W4390909200
Cited by
9
References
55
Citations by year
2026: 4 · 2025: 4 · 2024: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of North Texas Digital Library (University of North Texas) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (NRF-2014R1A6A1030318, NRF-2021R1I1A304950813)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
Hedgehog signaling, KRAS G12C inhibitors, acquired drug resistance, Gli1, primary cilia, AURKA, lung adenocarcinoma, Smoothened inhibitors
MeSH terms
Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), RNA, Small Interfering, Hedgehog Proteins, Aurora Kinase A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells. https://app.cochat.ai/papers/10.1038/s41419-024-06436-9
The paper
Lee, C., Yi, J., Park, J., Ahn, B., Won, Y.-W., Jeon, J., Lee, B. J., Cho, W. J., & Park, J. W. (2024). Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells. Cell Death & Disease. https://doi.org/10.1038/s41419-024-06436-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.